NCT06005714已完成1 期
Effect of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
Shanghai Vinnerna Biosciences Co., Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2023年8月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- AUC0-t of 116-N1
研究概览
简要总结
This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age: 18 years old ≤ age ≤ 45 years old; Gender is not limited;
- •Weight: male ≥ 50 kg, female ≥ 45 kg; Body mass index (BMI) in the range of 19-26 kg/m2 (including 19 and 26);
- •Good health status, that is, vital signs, physical examination, laboratory tests, electrocardiogram and ultrasound examination are normal or abnormal and have no clinical significance;
- •Participants who were able to take effective contraceptive measures during the study and within 3 months after the last dose of investigational product;
- •Participants who could fully understand the purpose, content and possible adverse reactions of this study, voluntarily participate in the clinical study and sign the written informed consent form, and were able to complete the entire study process and comply with the study regulations in accordance with the requirements of the study.
排除标准
- •Known history of allergy to the test preparation and any of its components or related preparations;
- •Subjects with allergic diseases or allergic constitutions;
- •Those who have clear diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic disorders, etc., and require medical intervention or other diseases that are not suitable for participating in clinical trials (such as psychiatric history, etc.);
- •Those who have donated blood or lost blood ≥ 400 mL within 3 months before enrollment, or have a history of blood product use;
- •Those who have participated in clinical trials of other drugs and taken experimental drugs within 3 months before enrollment;
- •Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health supplements within 2 weeks before screening;
- •Those who have used any vaccine within 2 weeks prior to screening.
- •Those who have previously undergone surgery (such as major gastrectomy surgery) that may affect drug absorption, distribution, metabolism, or excretion, or may have surgery or hospitalization plans during the estimated test;
- •Those with a history of drug dependence or abuse within 1 year before screening, or a positive urine drug screening test;
- •Those who have used P-gp or BCRP strong inhibitors within 2 weeks before screening (see Annex 6 of Section 10.6 for details);
- •Those who have ingested grapefruit juice/grapefruit juice, foods or drinks rich in methylxanthines (such as coffee, tea, cola, chocolate, functional drinks) within 48 hours before administration, or strenuous exercise and other factors that affect drug absorption, distribution, metabolism, excretion and other factors;
- •Alcohol addict within 1 year prior to screening, drinking at least 2 times a day or more than 14 units per week, or keen on alcoholism (1 unit≈ 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol or 85 mL of wine with 12% alcohol);
- •Those who smoked cigarettes within 1 year before screening, and smoked more than 10 cigarettes or the same amount of tobacco per day;
- •Those who cannot quit smoking or alcohol during the trial;
- •Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), treponemal antibody and HIV antibody positive;
- •Chest X-ray (positive and lateral view) results are abnormal and clinically significant;
- •At screening or baseline alanine aminotransferase (ALT) or glutamate aminotransferase (AST) exceeding the upper limit of normal (ULN);
- •Glomerular filtration rate (eGFR) at screening or baseline < 80 mL/min/1.73m2;
- •Abnormal ECG at screening or baseline, a single QTcF (mean of QT interval corrected by Fridericia formula) > 450 ms for men and 470 ms >for women, and/or other abnormalities of clinical significance;
- •Pregnant or lactating women or male subjects' spouses who have childcare plans within 3 months;
- •Those who have other factors that the investigator believes are not suitable for participation in the trial.
研究组 & 干预措施
The effects of clarithromycin on pharmacokinetics of deuterium hydrobromide ramidvir tablets
Experimental
干预措施: Mindeudesivir hydrobromide tablets and Clarithromycin tablets (Drug)
The effects of clarithromycin on pharmacokinetics of deuterium hydrobromide ramidvir tablets
Experimental
干预措施: Mindeudesivir hydrobromide tablets and Cyclosporine softgels (Drug)
The effects of cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets
Experimental
干预措施: Mindeudesivir hydrobromide tablets and Clarithromycin tablets (Drug)
The effects of cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets
Experimental
干预措施: Mindeudesivir hydrobromide tablets and Cyclosporine softgels (Drug)
结局指标
主要结局
AUC0-t of 116-N1
时间窗: At pre-defined intervals up to 14 days
Area under the curve from time zero to the time of the t(AUC0-t ) of 116-N1
Maximum Plasma Concentration (Cmax) of 116-N1
时间窗: At pre-defined intervals up to 14 days
Maximum Plasma Concentration (Cmax) of 116-N1
次要结局
- Vz/F of 116-N1(At pre-defined intervals up to 14 days)
- Tmax of 116-N1(At pre-defined intervals up to 14 days)
- Half-life(T1/2) of 116-N1(At pre-defined intervals up to 14 days)
- Clearance(CL) of 116-N1(At pre-defined intervals up to 14 days)
- Incidence and severity of adverse events including serious adverse events(Up to 18 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)Drug Drug InteractionNCT05845567Italfarmaco20
已完成
1 期
Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy SubjectsCLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]NCT02080780Ventrus Biosciences, Inc24
已完成
1 期
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsVenous ThromboembolismNCT02912234Bristol-Myers Squibb20
招募中
不适用
inezolid and clarithromycin drug-interaction study in multidrug-resistant and extensively drug-resistant tuberculosis patients.-'drug interaction'- linezolid- clarithromycin- multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB)in dutch/ in het nederlands:- geneesmiddelinteractie- linezolid- claritromycine- multidrug-resistente and extensieve drug-resistente tuberculose (MDR/XDR-TBC)NL-OMON24566niversity Medical Center GroningenA.t.t.n. Prof Dr JGW Kosterink, Department of Hospital and Clinical PharmacyP.O. Box 30.001; 9700 RB Groningen,The NetherlandsTel: +31 50 361 4071Fax: +31 50 361 4087Email: j.g.w.kosterink@umcg.nl7
已完成
1 期
A Study to Evaluate the Effect of Clarithromycin on LY2216684Depressive Disorder, MajorNCT01460407Eli Lilly and Company14